

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition consisting essentially of FSH and hCG in at least one pharmaceutically acceptable carrier, wherein the amount of FSH and hCG in said composition is ~~conducive, upon administration of said composition, to folliculogenesis and follicular maturation without ovarian hyperstimulation~~ selected from the group consisting of 50 IU FSH and 100 IU hCG; 50 IU FSH and 200 IU hCG; 75 IU FSH and 25 IU hCG; 75 IU FSH and 50 IU hCG; 75 IU FSH and 75 IU hCG; 75 IU FSH and 100 IU hCG; 150 IU FSH and 25 IU hCG; 150 IU FSH and 50 IU hCG; 150 IU FSH and 75 IU hCG; and 150 IU FSH and 100 IU hCG.
- 2-6. (Canceled)
7. (Currently Amended) The pharmaceutical composition of claim [[3]] 1 wherein the amount of FSH and hCG is selected from the group consisting of: 50 IU FSH and 100 IU hCG, 50 IU FSH and 200 IU hCG, and 50 IU FSH and 400 IU hCG.
8. (Currently Amended) The pharmaceutical composition of claim 7, wherein the amount of [[FHS]] FSH and hCG is 50 IU FSH and 100 IU hCG.
9. (Canceled)
10. (Canceled)
11. (Original) The pharmaceutical composition according to claim 1, wherein said FSH is human-derived FSH.
12. (Original) The pharmaceutical composition according to claim 1, in lyophilized form.
13. (Original) The pharmaceutical composition according to claim 1, in unit dosage form.
14. (Original) The pharmaceutical composition according to claim 13, in solid dosage form.

15. (Original) The pharmaceutical composition according to claim 14, wherein the solid dosage form is selected from the group consisting of capsules, tablets, suppositories, pills, powders, and granules.
16. (Original) The pharmaceutical composition according to claim 1 in liquid form.
17. (Original) The pharmaceutical composition according to claim 16 wherein the liquid form is supplied in a vial.
18. (Original) The pharmaceutical composition according to claim 16 wherein the liquid form is supplied in a pre-filled syringe or cartridge.
19. (Original) An assemblage comprising a first vial and a second vial, each of said vials containing a pharmaceutical composition according to claim 1, wherein the ratio of FSH to hCG differs between the first vial and the second vial.
20. (Original) The assemblage according to claim 19 further comprising written instructions on the timing for administering the compositions contained in the first and second vials.
21. (Withdrawn – Currently Amended) A method of inducing ovulation, comprising:
(A) administering at least one pharmaceutical composition characterized by an amount of FSH and hCG that is selected from the group consisting of: ~~50 IU FSH and 1 IU hCG, 50 IU FSH and 5 IU hCG, 50 IU FSH and 10 IU hCG, 50 IU FSH and 25 IU hCG, 50 IU FSH and 75 IU hCG, 50 IU FSH and 100 IU hCG, 50 IU FSH and 200 IU hCG, 50 IU FSH and 300 IU hCG, 50 IU FSH and 400 IU hCG, 75 IU FSH and 1 IU hCG, 75 IU FSH and 5 IU hCG, 75 IU FSH and 10 IU hCG, 75 IU FSH and 25 IU hCG, 75 IU FSH and 50 IU hCG, 75 IU FSH and 75 IU hCG, 75 IU FSH and 100 IU hCG, 75 IU FSH and 200 IU hCG, 75 IU FSH and 300 IU hCG, 75 IU FSH and 400 IU hCG, 100 IU FSH and 1 IU hCG, 100 IU FSH and 5 IU hCG, 100 IU FSH and 10 IU hCG, 100 IU FSH and 25 IU hCG, 100 IU FSH and 50 IU hCG, 100 IU FSH and 75 IU hCG, 100 IU FSH and 100 IU hCG, 100 IU FSH and 200 IU hCG, 100 IU FSH and 300 IU hCG, 100 IU FSH and 400 IU hCG, 150 IU FSH and 1 IU hCG, 150 IU FSH and 5 IU hCG, 150 IU FSH and 10 IU hCG, 150 IU FSH and 25 IU hCG, 150 IU~~

~~FSH and 100 IU hCG, 150 IU FSH and 200 IU hCG, 150 IU FSH and 300 IU hCG, 150 IU FSH and 400 IU hCG, 200 IU FSH and 1 IU hCG, 200 IU FSH and 5 IU hCG, 200 IU FSH and 10 IU hCG, 200 IU FSH and 25 IU hCG, 200 IU FSH and 50 IU hCG, 200 IU FSH and 75 IU hCG, 200 IU FSH and 100 IU hCG, 200 IU FSH and 200 IU hCG, 200 IU FSH and 300 IU hCG, and 200 IU FSH and 400 IU hCG~~ 50 IU FSH and 100 IU hCG; 50 IU FSH and 200 IU hCG; 75 IU FSH and 25 IU hCG; 75 IU FSH and 50 IU hCG; 75 IU FSH and 75 IU hCG; 75 IU FSH and 100 IU hCG; 150 IU FSH and 25 IU hCG; 150 IU FSH and 50 IU hCG; 150 IU FSH and 75 IU hCG; and 150 IU FSH and 100 IU hCG;

(B) monitoring serum hormone levels, follicle size and follicle number; and then

(C) inducing ovulation by administration of an hCG bolus.

Claims 22-24 (Canceled)

25. (Withdrawn – Currently Amended) The method of claim 21, wherein the amount of FSH and hCG is selected from the group consisting of: 50 IU FSH and 100 IU hCG ; and 50 IU FSH and 200 IU hCG ,~~and 50 IU FSH and 400 IU hCG.~~

26. (Withdrawn) The method of 21, wherein the amount of FSH and hCG is 50 IU FSH and 100 IU hCG.

Claims 27-28 (Canceled)

29. (Withdrawn) The method of claim 21 wherein step (A) comprises administering in series at least two of said pharmaceutical compositions, wherein the amount of FSH and hCG in said compositions is either the same or different.

30. (Withdrawn) The method of claim 29, wherein each succeeding composition in said series contains hCG that is increased over the preceding composition in said series.

31. (Withdrawn) The method of claim 29, wherein the period of time between the administrations of the series is selected from the group consisting of: from 1 hour, 5 hours, 10 hours, 12, hours, 24 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6, days, 7, days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, and 16 days.

32. (Withdrawn) The method of claim 21, further comprising administration of pure FSH.

33. (Withdrawn) The method of claim 21, further comprising administration of pure hCG.

34. (Currently Amended) A product comprising a first pharmaceutical composition comprising FSH and a second pharmaceutical composition comprising hCG, wherein the amount of hCG in the second pharmaceutical composition is selected from the group consisting of 1, 2, 3, 4 or 8 μ g hCG.

Claim 35 (Canceled)

36. (Original) The product of claim 34, further comprising instructions for using the first and second pharmaceutical compositions.

37. (Original) The product of claim 34, further comprising a means for administering the first and second pharmaceutical compositions.

38. (Withdrawn-Currently Amended) A method of treating infertility comprising administering a pharmaceutical composition comprising hCG and a pharmaceutical composition comprising FSH, wherein the amount of FSH and hCG in said composition is selected from the group consisting of 50 IU FSH and 100 IU hCG; 50 IU FSH and 200 IU hCG; 75 IU FSH and 25 IU hCG; 75 IU FSH and 50 IU hCG; 75 IU FSH and 75 IU hCG; 75 IU FSH and 100 IU hCG; 150 IU FSH and 25 IU hCG; 150 IU FSH and 50 IU hCG; 150 IU FSH and 75 IU hCG; and 150 IU FSH and 100 IU hCG..

39. (Cancelled)

40. (Withdrawn) The method according to claim 38 for stimulating folliculogenesis or ovulation.

41. (Withdrawn) The method according to claim 40, comprising administering an amount of FSH and hCG that is conducive to folliculogenesis and follicular maturation without ovarian hyperstimulation.

Claims 42-43 (Canceled)

44. (Currently Amended) A product ~~according to claim 34~~ comprising a first pharmaceutical composition comprising FSH and a second pharmaceutical composition comprising hCG, wherein the amount of hCG in the second pharmaceutical composition is between 0.04 and 16 μg .

45. (Currently Amended) A product ~~according to claim 34~~ comprising a first pharmaceutical composition comprising FSH and a second pharmaceutical composition comprising hCG, wherein the amount of FSH in the first pharmaceutical composition is from about 1.0 μg to about 2,000 mg/ml.

46. (Currently Amended) A product ~~according to claim 34~~ comprising a first pharmaceutical composition comprising FSH and a second pharmaceutical composition comprising hCG, wherein the amount of hCG in the second pharmaceutical composition is about 0.1 μg to about 2,000 mg/ml.

47. (Currently Amended) A product ~~according to claim 34~~ comprising a first pharmaceutical composition comprising FSH and a second pharmaceutical composition comprising hCG, wherein the amount of FSH in the first pharmaceutical composition is from about 1.0 μg to about 2,000 mg/ml and the amount of hCG in the second pharmaceutical composition is about 0.1 μg to about 2,000 mg/ml.

48. (New) The product of claim 36, wherein said instructions direct the sequential administration of said compositions.

49. (New) A pharmaceutical composition consisting essentially of FSH and hCG in at least one pharmaceutically acceptable carrier, wherein the amount of FSH and hCG in said composition is conducive, upon administration of said composition, to folliculogenesis and follicular maturation without ovarian hyperstimulation.